Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared ...

Novavax Inc. shares climbed 2% on Wednesday and extended gains in after-hours trading, as retail investors maintained a ...

The Lowe's Foundation today announced nearly $9 million in Gable Grants to strengthen 15 nonprofits on the front lines of a growing skilled trades workforce movement. From Alaska to Mississippi, each ...

Novavax reported a Q4 2024 EPS of -$0.51, surpassing expectations. Revenue for the quarter fell to $88.3 million, missing forecasts and down from $291 million in Q4 2023. The company reduced R&D ...

Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial by next month and potential ...

To meet growing customer demand for multicloud capabilities, Oracle today announced the general availability of the Oracle US Gov West (Phoenix) and Azure US Gov Arizona (Phoenix) regions for Oracle ...